Table 1 Characteristics of myositis incident patients (2004–2008)
Commercial and Medicare patients | Medicaid patients | |||
|---|---|---|---|---|
n | % | n | % | |
Myositis (Overall) 1 | 2,477 | 100% | 513 | 100.0% |
Dermatomyositis | 902 | 36.4% | 170 | 33.1% |
Polymyositis | 1,438 | 58.1% | 346 | 67.4% |
Interstitial myositis | 401 | 16.2% | 75 | 14.6% |
Year | ||||
2004 | 436 | 17.6% | 190 | 37.0% |
2005 | 522 | 21.1% | 108 | 21.1% |
2006 | 502 | 20.3% | 64 | 12.5% |
2007 | 555 | 22.4% | 87 | 17.0% |
2008 | 462 | 18.6% | 64 | 12.5% |
Age | ||||
18-24 | 60 | 2.4% | 31 | 6.0% |
25-34 | 123 | 5.0% | 53 | 10.3% |
35-44 | 292 | 11.8% | 91 | 17.7% |
45-54 | 558 | 22.5% | 111 | 21.6% |
55-64 | 748 | 30.2% | 116 | 22.6% |
65-74 | 392 | 15.8 | 63 | 12.3 |
75+ | 304 | 12.3 | 48 | 9.4% |
Gender | ||||
Female | 1,612 | 65.1 | 397 | 77.4% |
Male | 865 | 34.9% | 116 | 22.6% |
Race/Ethnicity (N, %) | ||||
Caucasian | …. | …. | 193 | 37.6% |
African American | …. | …. | 220 | 42.9% |
Hispanic | …. | …. | 25 | 4.9% |
Other/Unknown | …. | …. | 7 | 1.4% |
Region | ||||
Northeast | 289 | 11.7% | …. | …. |
North Central | 756 | 30.5% | …. | …. |
South | 956 | 38.6% | …. | …. |
West | 461 | 18.6% | …. | …. |
Unknown | 15 | 0.6% | …. | …. |
Urbanization | ||||
Urban | 2,087 | 84.7% | …. | …. |
Rural | 380 | 15.3% | …. | …. |
Unknown | 10 | 0.4% | …. | …. |
Medicare | 699 | 28.2 % | 228 | 44.4% |
Fee-for-service (N, %) | ||||
Fee-for-service | 1,443 | 58.3% | 362 | 70.6% |
Not fee-for-service | 1,034 | 41.7% | 150 | 29.2% |
Unknown | 0 | 0% | 1 | 0.2% |
Clinical Conditions (365 days before index date) | ||||
Rheumatoid Arthritis | 170 | 6.9% | 51 | 9.9% |
Systemic lupus erythematosus | 158 | 6.4% | 41 | 8.0% |
Systemic sclerosis | 44 | 1.8% | 12 | 2.3% |
Cushing syndrome | 3 | 0.1% | 1 | 0.2% |
Addison's disease | 10 | 0.4% | 6 | 1.2% |
Other Inflammatory Arthritis/Arthropathies | 563 | 22.7% | 151 | 29.4% |
Back problems | 654 | 26.4% | 139 | 27.1% |
Dysphagia | 130 | 5.2% | 29 | 5.7% |
Hypertension | 897 | 36.2% | 256 | 49.9% |
Diabetes | 385 | 15.5 % | 159 | 31.0% |
Depression | 164 | 6.6% | 103 | 20.1% |
Malignancy | 259 | 10.5% | 52 | 10.1% |
Medications on or 365 days after index date | ||||
Systemic corticosteroid | 1852 | 74.8% | 321 | 62.6% |
Topical corticosteroid | 1722 | 69.5% | 294 | 57.3% |
Methotrexate | 650 | 26.2% | 73 | 14.2% |
Azathioprine | 352 | 14.2% | 64 | 12.5% |
Hydroxychloroquine | 353 | 14.3% | 51 | 9.9% |
Intravenous immunoglobulin | 24 | 1.0% | 6 | 1.2% |
Cyclosporine | 62 | 2.5% | 6 | 1.2% |
Mycophenolate mofetil | 136 | 5.5% | 16 | 3.1% |
Leflunomide | 17 | 0.7% | 5 | 1.0% |
Thalidomide | 1 | 0.0% | 0 | 0.0% |
Cyclophosphamide | 34 | 1.4% | 9 | 1.8% |
Tacrolimus | 50 | 2.0 % | 5 | 1.0% |
Rituximab | 24 | 1.0% | 2 | 0.4% |